Bone modeling indexes at onset and during the first year of follow-Up in insulin-dependent diabetic children.
Osteopenia has been described as a complication of insulin-dependent diabetes mellitus (IDDM). We measured bone modeling indexes during the first year of IDDM. At each time point the values obtained from diabetic children have been compared with those of control subjects. We selected 27 prepubertal children with IDDM (6.35 +/- 2.16 years). We also enrolled 30 healthy prepubertal children of comparable age (5.85 +/- 3.05 years). Height, height standard deviation scores, glycated haemoglobin (HbA1C), basal c-peptide concentrations, insulin dose, serum concentrations of procollagen type I C-terminal propeptide (PICP), and collagen type I C-terminal telopeptide (ICTP) were measured at onset of IDDM and at 3, 6 and 12 months. ICTP was in the normal range at onset of IDDM and decreased during the follow-up to reach a significant difference compared to controls after 3, 6 and 12 months of insulin treatment (P < 0.04). PICP concentrations increased significantly at 3 months (P = 0.05) compared to onset. At 3 and 12 months PICP values were significantly higher than those of control children (P = 0.04). Correlations were found between PICP concentrations and HbA1C and c-peptide at onset of diabetes (r = -0.45 and r = 0.47, respectively). Bone formation at onset of IDDM is not impaired; the introduction of insulin therapy, together with the achievement of a good metabolic control, determines an increase of bone matrix formation coupled with a decrease of bone resorption, that determines a positive balance of bone modeling.
Bonfanti
R
R
Laboratory of Pediatric Endocrinology, Department of Pediatrics, Scientific Institute H San Raffaele, via Olgettina 60, 20132 MILANO MI, University of Milan, Milan, Italy.
Mora
S
S
Prinster
C
C
Bognetti
E
E
Meschi
F
F
Puzzovio
M
M
Proverbio
M C
MC
Chiumello
G
G
D000293:Adolescent; D015415:Biomarkers / Q000097:blood; D001827:Body Height; D001835:Body Weight; D001846:Bone Development; D001851:Bone Diseases, Metabolic / Q000209:etiology; D002096:C-Peptide / Q000097:blood; D002648:Child; D015331:Cohort Studies; D003094:Collagen / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D012016:Reference Values; D012044:Regression Analysis; D013997:Time Factors
D015415:Biomarkers; D002096:C-Peptide; D003094:Collagen; D006442:Glycated Hemoglobin; D007328:Insulin; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide